Last reviewed · How we verify
NCT05454280
Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II)
Phase 3 trial testing Intensified post-discharge surveillance in Surgery in 880 participants. Currently enrolling.
1 November 2028
Quick facts
| Lead sponsor | Fox Chase Cancer Center |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 880 |
| Start date | 14 October 2022 |
| Primary completion | 1 November 2028 |
| Estimated completion | 1 November 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Intensified post-discharge surveillance
- Standard post-discharge surveillance
Conditions studied
Sponsor
Fox Chase Cancer Center — full company profile →
Who can join
18 and older, any sex, with Surgery or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized trial of intensified post-discharge surveillance (Intervention Arm) versus standard post-discharge surveillance (Control Arm).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05454280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Surgery
Currently open trials in the same condition.
- NCT07369921 — Pediatric Pilonidal Sinus Surgical Treatment · NA · recruiting
- NCT07362303 — Neuralert Stroke Monitor Trial · NA · recruiting
- NCT07404163 — Walkway Used in Postoperative Mobilization · NA · active not recruiting
- NCT07218289 — Green Light for Post-Operative Wellness · NA · recruiting
- NCT07342751 — The Effect of Listening to Music During Mobilization on Pain and Fear in Children Undergoing Abdominal Surgery · NA · active not recruiting
Other Fox Chase Cancer Center trials
Trials by the same sponsor.
- NCT07455032 — Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous · Phase 1 · recruiting
- NCT07221942 — Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma · Phase 2 · recruiting
- NCT07221058 — Adaptive Radiation Boost for Rectal Cancer · Phase 1 · recruiting
- NCT07167446 — Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy · EARLY_PHASE1 · recruiting
- NCT07219303 — Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05454280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Fox Chase Cancer Center
- Last refreshed: 8 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05454280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing